The EPS miss is significant for a micro-cap biotech, but the merger with Scipher Medicine is the primary catalyst. Monitor for merger closing updates and any regulatory milestones for nebokitug in RA. The stock's low liquidity and high volatility warrant caution.
Price Chart
Executive Summary
Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no revenue. The planned merger with Scipher Medicine to advance nebokitug into a Phase 2 RA trial is progressing, with closing expected by year-end. The significant EPS miss and lack of revenue highlight the pre-revenue clinical-stage nature of the company, but the merger catalyst provides a potential value inflection point.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.24 missed consensus of $0.00 by 51.8%
- No revenue reported for the quarter
- Planned merger with Scipher Medicine to assess nebokitug in Phase 2 RA trial continues, closing expected by year-end
- Market cap of $14M with 88% analyst bullish rating
Financial Impact
EPS miss of -$0.24 vs $0 consensus; no revenue; merger value undisclosed
Risk Factors
- Merger may not close as expected
- Nebokitug Phase 2 RA trial could fail
- Cash burn without revenue may require dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3347616 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 6-K | $2.09 $2.80 | ▲ +33.97% | ▲ +35.92% | $1.30 (−37.80%) |
Aug 19, 2026 6w ago | Press Release | $2.09 $2.80 | ▼ −33.97% | ▼ −35.92% | $1.30 (+37.80%) |
Jul 8, 2026 12w ago | 6-K | $1.97 $1.75 | ▼ −11.17% | ▼ −14.44% | $1.30 (−34.01%) |
Jun 2, 2026 17w ago | 6-K | $1.72 $2.27 | ▲ +31.98% | ▲ +32.98% | $1.30 (−24.42%) |
May 14, 2026 20w ago | 6-K | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 14, 2026 20w ago | Press Release | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 6, 2026 21w ago | 6-K | $1.74 $1.72 | ▼ −1.15% | ▼ −4.29% | $1.30 (−25.29%) |
Mar 19, 2026 28w ago | Press Release | $1.93 $1.67 | ▼ −13.47% | ▼ −21.09% | $1.30 (−32.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access